Acceleron Pharma (NASDAQ:XLRN) had its price target upped by HC Wainwright from $66.00 to $69.00 in a research report sent to investors on Monday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts have also commented on XLRN. BidaskClub lowered Acceleron Pharma from a hold rating to a sell rating in a research report on Friday, April 5th. ValuEngine lowered Acceleron Pharma from a strong-buy rating to a buy rating in a research report on Thursday, April 18th. Barclays lowered Acceleron Pharma from an overweight rating to an equal weight rating and lowered their price target for the company from $54.00 to $45.00 in a research report on Friday, May 3rd. Oppenheimer reaffirmed an outperform rating on shares of Acceleron Pharma in a research report on Monday, April 22nd. Finally, Zacks Investment Research raised Acceleron Pharma from a hold rating to a buy rating and set a $46.00 price target for the company in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company’s stock. Acceleron Pharma presently has a consensus rating of Buy and an average price target of $57.70.
NASDAQ XLRN opened at $41.92 on Monday. Acceleron Pharma has a 1-year low of $32.53 and a 1-year high of $59.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 19.26 and a quick ratio of 16.18. The stock has a market capitalization of $2.21 billion, a PE ratio of -16.19 and a beta of 1.31.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). Acceleron Pharma had a negative net margin of 965.39% and a negative return on equity of 35.94%. The company had revenue of $2.78 million during the quarter, compared to the consensus estimate of $3.67 million. During the same period last year, the firm posted ($0.58) EPS. The company’s revenue was down 13.9% on a year-over-year basis. Equities research analysts forecast that Acceleron Pharma will post -2.31 earnings per share for the current year.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 648 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $48.02, for a total transaction of $31,116.96. Following the transaction, the chief financial officer now owns 42,279 shares in the company, valued at approximately $2,030,237.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Habib J. Dable sold 7,460 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $44.60, for a total value of $332,716.00. Following the transaction, the chief executive officer now owns 76,754 shares in the company, valued at approximately $3,423,228.40. The disclosure for this sale can be found here. Insiders have sold a total of 23,730 shares of company stock valued at $1,060,959 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. Clarfeld Financial Advisors LLC purchased a new position in shares of Acceleron Pharma during the 4th quarter worth approximately $44,000. Citizens Financial Group Inc RI purchased a new position in shares of Acceleron Pharma during the 1st quarter worth approximately $47,000. Quadrant Capital Group LLC purchased a new position in shares of Acceleron Pharma during the 1st quarter worth approximately $46,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Acceleron Pharma during the 4th quarter worth approximately $113,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Acceleron Pharma by 17.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,602 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 386 shares during the period. Hedge funds and other institutional investors own 85.05% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Featured Story: S&P 500 Index
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.